Oral Ketamine in Burn Wound Care: Clinical Evidence and Policy Outlook

Oral Ketamine Demonstrated as Adjunct for Burn Wound Pain

A peer-reviewed study published on November 4, 2026, in PubMed (PMID: 42696301) reports that oral ketamine may serve as an effective adjunctive therapy for pain management during burn wound care. The research provides new clinical data supporting ketamine’s use outside its established roles in anesthesia and psychiatry, specifically targeting acute pain in patients with burn injuries. This finding is significant given the ongoing search for alternatives to opioid analgesics in acute care settings.

Mechanism and Context: Ketamine’s Role in Acute Pain Management

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, modulates pain perception by inhibiting excitatory neurotransmission in the central nervous system. In the context of burn wound care, oral ketamine may reduce pain intensity and opioid requirements, potentially minimizing opioid-related adverse effects such as respiratory depression and dependence. The study’s focus on oral administration is notable, as most ketamine research in acute care has centered on intravenous or intramuscular routes, which require more intensive monitoring and resources. Oral ketamine’s relative ease of administration could make it a pragmatic option in resource-limited or outpatient settings, though its pharmacokinetics and bioavailability differ from parenteral forms.

Policy and Research Implications: Protocols and Regulatory Considerations

The study’s findings may inform updates to clinical protocols for burn care, particularly in hospitals seeking to diversify pain management strategies. However, ketamine’s current regulatory status in the United States and most jurisdictions restricts its use to approved indications—primarily anesthesia and, in some cases, treatment-resistant depression. Off-label use for acute pain remains at the discretion of individual clinicians and institutions, often guided by local policy and risk management frameworks. Without larger phase III trials or regulatory review by agencies such as the U.S. Food and Drug Administration (FDA), broad adoption of oral ketamine for burn wound care is unlikely. Notably, this study may encourage hospital ethics committees and pharmacy and therapeutics (P&T) committees to revisit their formularies and protocols, especially in light of the ongoing opioid crisis and the need for effective non-opioid analgesics.

• First-party sourcing: The study is indexed in PubMed (PMID: 42696301), providing a primary source for clinicians and policymakers reviewing evidence for ketamine’s repurposing.
• Non-obvious implication: The oral route’s feasibility could make ketamine accessible in settings lacking anesthesia infrastructure, but it also introduces new challenges for dosing consistency and abuse prevention—factors often overlooked in acute care protocol discussions.

Risks, Unknowns, and Barriers to Adoption

Despite promising results, several risks and unknowns remain. Ketamine’s side effect profile includes dissociation, hallucinations, and potential for misuse, which may be more pronounced with oral administration due to variable absorption and delayed onset. The study’s sample size and duration may limit generalizability, and long-term safety data in burn populations are lacking. Additionally, the risk of diversion and non-medical use is a concern for hospital pharmacy and regulatory authorities, especially if oral formulations become more widely available. These factors necessitate careful patient selection, monitoring protocols, and staff training if oral ketamine is to be integrated into burn care pathways.

Forward Outlook: Research, Funding, and Clinical Practice

Future research should prioritize multicenter, randomized controlled trials to validate efficacy and safety, as well as pharmacokinetic studies to optimize dosing regimens for oral ketamine in acute pain. Funding agencies and institutional review boards may be more receptive to such studies given the dual pressures of the opioid epidemic and the need for scalable pain management solutions. Meanwhile, clinicians and hospital administrators should weigh the potential benefits of oral ketamine against operational risks and regulatory uncertainty. As the evidence base grows, professional societies and regulatory agencies may consider issuing guidance or initiating formal review processes, which could pave the way for broader, evidence-based adoption in acute care settings.

Authored by Dr. Alex M. Carter, MD, MPH. Reviewed by Dr. Lisa Tran, PharmD, on 2026-11-06. Research based on primary source: PubMed (PMID: 42696301).